Insulinemic response

The insulinemic response is a complex physiological process characterized by the secretion and subsequent elevation of insulin levels in the blood, typically occurring after the ingestion of nutrients such as glucose or proteins. It is a vital component of metabolic regulation, facilitating the uptake of glucose into peripheral tissues like muscle and adipose tissue while suppressing hepatic glucose production to maintain euglycemia (StatPearls, 2023). In clinical medicine, the insulinemic response is not considered a direct molecular target but rather a pharmacodynamic endpoint or biomarker used to assess the efficacy of metabolic therapies (NIH, 2023). Dysregulation of this response is a primary feature of metabolic disorders; for instance, a delayed or insufficient response is characteristic of type 2 diabetes, whereas a chronically elevated response is a hallmark of insulin resistance (PubMed, 2022). Therapeutic strategies often aim to optimize this response using drugs that act on specific molecular targets, such as the GLP-1 receptor or potassium channels, to improve long-term glycemic control and reduce cardiovascular risk. Because it represents a systemic outcome of multiple signaling pathways rather than a single molecule, it remains an essential measure for clinical evaluation rather than a druggable receptor or enzyme.

Other names

Postprandial insulin responseInsulin secretion profileHyperinsulinemic responseInsulinemic index

Drugs modulate the insulinemic response through various indirect pathways, such as agonizing the glucagon-like peptide-1 receptor (GLP1R) to enhance glucose-dependent insulin secretion or inhibiting dipeptidyl peptidase-4 (DPP-4) to prolong incretin action.